Volker Gross
Research Subjects
Volker Gross has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
A. Lavy
Bnai Tzion Medical Center, Haifa, Israel
1 shared publicationA. Razbadauskas
Klaipėdos Jūrininku lignine, Klaipėda, Lithuania
1 shared publication- Andreas Georg Schreyer
Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Brandenburg an der Havel – Medizinische Hochschule Brandenburg Theodor Fontane, Brandenburg an der Havel, Deutschland
1 shared publication Andrey E. Dorofeyev
1 shared publicationB. Margus
East Tallinn Central Hospital, Tallinn, Estonia
1 shared publicationC.-T Germer
1 shared publication
Latest Publications
- 1 June 2013
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 155 (12) , 47-50
So wird stadiengerecht behandelt
- 1 June 2013
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 155 (12) , 47-50
So wird stadiengerecht behandelt
- 6 September 2012
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 137 (37) , 1803-1805
Immunsuppression bei chronisch-entzündlichen Darmerkrankungen: Wann, wie und wie lange?
Die immunsuppressive Therapie ist wichtiger Bestandteil der Behandlung von Patienten mit chronisch entzündlicher Darmerkrankung. Therapieziel ist das Erreichen einer langfristigen Remission. Kandidaten für eine immunsuppressive Therapie sind Patienten mit steroidrefraktären akuten Krankheitsschüben, Steroidabhängigkeit , chronisch aktivem Verlauf oder häufigen Rezidiven. Zur Verfügung stehen konventionelle Immunsuppressiva, in erster Linie Azathioprin/6-Mercaptopurin, weiterhin Methotrexat und die Calcineurin-Inhibitoren Cyclosporin A und Tacrolimus sowie die Anti-TNF-Antikörper Infliximab und Adalimumab. Aktuelle Leitlinien setzen den Rahmen für den rationalen Einsatz dieser Medikamente zur Remissionsinduktion und Remissionserhaltung. Immunosuppressive treatment is an important tool in the therapy of patients with inflammatory bowel disease. Treatment goal is a long lasting remission. Candidates for immunosuppressive treatment are patients with steroid-refractory active disease, steroid-dependency, chronic active disease or frequent relapses. Conventional immunosuppressives (azathioprine/6-mercaptopurine, methotrexate, the calcineurin inhibitors cyclosporine A and tacrolimus), and anti-TNF antibodies (infliximab, adalimumab) are available. Current guidelines set the frame for the rational use of these drugs.
- 6 September 2012
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 137 (37) , 1803-1805
Immunsuppression bei chronisch-entzündlichen Darmerkrankungen: Wann, wie und wie lange?
Die immunsuppressive Therapie ist wichtiger Bestandteil der Behandlung von Patienten mit chronisch entzündlicher Darmerkrankung. Therapieziel ist das Erreichen einer langfristigen Remission. Kandidaten für eine immunsuppressive Therapie sind Patienten mit steroidrefraktären akuten Krankheitsschüben, Steroidabhängigkeit , chronisch aktivem Verlauf oder häufigen Rezidiven. Zur Verfügung stehen konventionelle Immunsuppressiva, in erster Linie Azathioprin/6-Mercaptopurin, weiterhin Methotrexat und die Calcineurin-Inhibitoren Cyclosporin A und Tacrolimus sowie die Anti-TNF-Antikörper Infliximab und Adalimumab. Aktuelle Leitlinien setzen den Rahmen für den rationalen Einsatz dieser Medikamente zur Remissionsinduktion und Remissionserhaltung. Immunosuppressive treatment is an important tool in the therapy of patients with inflammatory bowel disease. Treatment goal is a long lasting remission. Candidates for immunosuppressive treatment are patients with steroid-refractory active disease, steroid-dependency, chronic active disease or frequent relapses. Conventional immunosuppressives (azathioprine/6-mercaptopurine, methotrexate, the calcineurin inhibitors cyclosporine A and tacrolimus), and anti-TNF antibodies (infliximab, adalimumab) are available. Current guidelines set the frame for the rational use of these drugs.
- 1 May 2012
- Published by S. Karger AG in Digestive Diseases
- Vol. 30 (1) , 92-99
Aminosalicylates
Symptomatic diverticular disease has a high prevalence in countries with a western lifestyle. Besides antibiotics for acute diverticulitis there are no established medical interventions to prevent or to treat symptomatic diverticular disease. Due to its broad spectrum of anti-inflammatory activities, mesalazine is a candidate for the treatment of symptomatic diverticular disease. A review of the literature shows that randomized open studies using various treatment designs suggest a protective role of mesalazine in preventing recurrences of diverticulitis. Currently, 5 randomized placebo-controlled trials are active which will clarify the role of mesalazine to prevent recurrence of diverticulitis in the near future. Several randomized uncontrolled studies suggest that mesalazine improves symptoms in patients with symptomatic uncomplicated diverticular disease. The analysis of secondary end points from two randomized placebo-controlled trials suggests that mesalazine improves symptoms in diverticular disease although both studies failed to show a statistically significant advantage for mesalazine for the primary study end point. In segmental colitis associated with diverticulosis no prospective systematic studies are available. However, several case reports show a high efficacy of mesalazine in segmental colitis associated with diverticulosis.
- 1 May 2012
- Published by S. Karger AG in Digestive Diseases
- Vol. 30 (1) , 92-99
Aminosalicylates
Symptomatic diverticular disease has a high prevalence in countries with a western lifestyle. Besides antibiotics for acute diverticulitis there are no established medical interventions to prevent or to treat symptomatic diverticular disease. Due to its broad spectrum of anti-inflammatory activities, mesalazine is a candidate for the treatment of symptomatic diverticular disease. A review of the literature shows that randomized open studies using various treatment designs suggest a protective role of mesalazine in preventing recurrences of diverticulitis. Currently, 5 randomized placebo-controlled trials are active which will clarify the role of mesalazine to prevent recurrence of diverticulitis in the near future. Several randomized uncontrolled studies suggest that mesalazine improves symptoms in patients with symptomatic uncomplicated diverticular disease. The analysis of secondary end points from two randomized placebo-controlled trials suggests that mesalazine improves symptoms in diverticular disease although both studies failed to show a statistically significant advantage for mesalazine for the primary study end point. In segmental colitis associated with diverticulosis no prospective systematic studies are available. However, several case reports show a high efficacy of mesalazine in segmental colitis associated with diverticulosis.
- 1 April 2011
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 5 (2) , 129-138
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial
Budesonide may be an effective therapy for mild-to-moderately active ulcerative colitis (UC). This study aimed to demonstrate non-inferiority for oral 9mg budesonide once daily (OD) versus 3g mesalazine granules OD. This was an eight-week randomised, double-blind, double-dummy, multicentre study in which patients with mild-to-moderately active UC, defined as Clinical Activity Index (CAI) ≥6 and Endoscopic Index (EI) ≥4, received budesonide (Budenofalk® 3mg capsules×3) or mesalazine (Salofalk® 1000mg granules×3). The primary endpoint was clinical remission at week 8 (CAI ≤4 with stool frequency and rectal bleeding subscores of "0"). 343 patients were randomised (177 budesonide, 166 mesalazine). Fewer patients achieved the primary endpoint with budesonide versus mesalazine (70/177 [39.5%] versus 91/166 [54.8%]) with a difference in proportions of -15.3% (95% CI [-25.7%, -4.8%]; p=0.520 for non-inferiority). The median time to first resolution of symptoms was 14.0 days (budesonide) and 11.0 days (mesalazine) (hazard ratio 1.19; 95% CI [0.94, 1.51]). Mucosal healing was observed in 54/177 (30.5%) budesonide patients versus 65/166 (39.2%) mesalazine patients, a difference of -8.6% (95% CI [-18.7%, 1.4%]; p=0.093). The incidences of adverse events (budesonide 26.6%, mesalazine 25.3%) and serious adverse events (budesonide 1.7%, mesalazine 1.2%) were similar. Once-daily 3g mesalazine administered as granules is superior to 9mg budesonide OD administered as capsules for achieving remission in mild-to-moderately active UC. However, it is noteworthy that remission of UC was attained in about 40% of budesonide-treated patients with a rapid onset of resolution.
- 1 April 2011
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 5 (2) , 129-138
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial
Budesonide may be an effective therapy for mild-to-moderately active ulcerative colitis (UC). This study aimed to demonstrate non-inferiority for oral 9mg budesonide once daily (OD) versus 3g mesalazine granules OD. This was an eight-week randomised, double-blind, double-dummy, multicentre study in which patients with mild-to-moderately active UC, defined as Clinical Activity Index (CAI) ≥6 and Endoscopic Index (EI) ≥4, received budesonide (Budenofalk® 3mg capsules×3) or mesalazine (Salofalk® 1000mg granules×3). The primary endpoint was clinical remission at week 8 (CAI ≤4 with stool frequency and rectal bleeding subscores of "0"). 343 patients were randomised (177 budesonide, 166 mesalazine). Fewer patients achieved the primary endpoint with budesonide versus mesalazine (70/177 [39.5%] versus 91/166 [54.8%]) with a difference in proportions of -15.3% (95% CI [-25.7%, -4.8%]; p=0.520 for non-inferiority). The median time to first resolution of symptoms was 14.0 days (budesonide) and 11.0 days (mesalazine) (hazard ratio 1.19; 95% CI [0.94, 1.51]). Mucosal healing was observed in 54/177 (30.5%) budesonide patients versus 65/166 (39.2%) mesalazine patients, a difference of -8.6% (95% CI [-18.7%, 1.4%]; p=0.093). The incidences of adverse events (budesonide 26.6%, mesalazine 25.3%) and serious adverse events (budesonide 1.7%, mesalazine 1.2%) were similar. Once-daily 3g mesalazine administered as granules is superior to 9mg budesonide OD administered as capsules for achieving remission in mild-to-moderately active UC. However, it is noteworthy that remission of UC was attained in about 40% of budesonide-treated patients with a rapid onset of resolution.
- 9 May 2010
- Published by Springer Nature in Der Gastroenterologe
- Vol. 5 (3) , 215-221
Chronisch-entzündliche Darmerkrankungen
- 9 May 2010
- Published by Springer Nature in Der Gastroenterologe
- Vol. 5 (3) , 215-221
Chronisch-entzündliche Darmerkrankungen
- 30 June 2008
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 133 (27) , 1437-1446
Divertikulose und Divertikulitis
Divertikulose - Divertikulitis - Diagnostik - Therapie - Sonographie - Computertomographie divertikulosis - divertikulitis - diagnosis - therapy - ultrasound - computed tomography
- 30 June 2008
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 133 (27) , 1437-1446
Divertikulose und Divertikulitis
Divertikulose - Divertikulitis - Diagnostik - Therapie - Sonographie - Computertomographie divertikulosis - divertikulitis - diagnosis - therapy - ultrasound - computed tomography
- 26 June 2008
- Vol. 150, 41-3
[Diagnostic workup of chronic diarrhoea].
- 21 April 2008
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 9 (7) , 1257-1265
Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis
Background: Budesonide is a glucocorticoid with high topical glucocorticoid activity and low systemic availability. Oral pH-modified release budesonide has been investigated for the treatment of various inflammatory intestinal diseases. Objective: To summarise the investigational data of oral pH-modified release budesonide for the treatment of Crohn's disease, ulcerative colitis, collagenous colitis and lymphocytic colitis. Methods: Assessment of all published (full paper or meeting abstract) clinical studies with oral pH-modified release budesonide for the treatment of inflammatory intestinal diseases. Results/conclusion: Oral pH-modified release budesonide induces remission in mild-to-moderately active Crohn's disease of the ileum and/or ascending colon. This drug is useful to replace conventional systemic glucocorticoids in patients with ileocoecal Crohn's disease. Open-label studies showed efficacy in ulcerative colitis, but this finding has to be confirmed in controlled trials. Oral pH-modified relea...
- 21 April 2008
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 9 (7) , 1257-1265
Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis
Background: Budesonide is a glucocorticoid with high topical glucocorticoid activity and low systemic availability. Oral pH-modified release budesonide has been investigated for the treatment of various inflammatory intestinal diseases. Objective: To summarise the investigational data of oral pH-modified release budesonide for the treatment of Crohn's disease, ulcerative colitis, collagenous colitis and lymphocytic colitis. Methods: Assessment of all published (full paper or meeting abstract) clinical studies with oral pH-modified release budesonide for the treatment of inflammatory intestinal diseases. Results/conclusion: Oral pH-modified release budesonide induces remission in mild-to-moderately active Crohn's disease of the ileum and/or ascending colon. This drug is useful to replace conventional systemic glucocorticoids in patients with ileocoecal Crohn's disease. Open-label studies showed efficacy in ulcerative colitis, but this finding has to be confirmed in controlled trials. Oral pH-modified relea...
- Open Access
- 22 December 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 23 (2) , 303-312
Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis
Summary: Background Rectal budesonide is an effective treatment of active ulcerative proctitis or proctosigmoiditis.Aim To compare the therapeutic efficacy, tolerability and safety, and patient's preference of budesonide foam vs. budesonide enema.Methods Patients with active ulcerative proctitis or proctosigmoiditis (clinical activity index >4 and endoscopic index ≥4) were eligible for this double‐blind, double‐dummy, randomized, multicentre study. They received 2 mg/25 mL budesonide foam and placebo enema (n = 265), or 2 mg/100 mL budesonide enema and placebo foam (n = 268) for 4 weeks. Primary endpoint was clinical remission (clinical activity index ≤4) at the final/withdrawal visit (per protocol).Results A total of 541 patients were randomized – 533 were evaluable for intention‐to‐treat analysis and 449 for per protocol analysis. Clinical remission rates (per protocol) were 60% for budesonide foam and 66% for budesonide enema (P = 0.02362 for non‐inferiority of foam vs. enema within a predefined non‐inferiority margin of 15%). Both formulations were safe and no drug‐related serious adverse events were observed. Because of better tolerability and easier application most patients preferred foam (84%).Conclusion Budesonide foam is as effective as budesonide enema in the treatment of active ulcerative proctitis or proctosigmoiditis. Both budesonide formulations are safe, and most patients prefer foam.
- 22 December 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 23 (2) , 303-312
Open AccessBudesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis
Summary: Background Rectal budesonide is an effective treatment of active ulcerative proctitis or proctosigmoiditis.Aim To compare the therapeutic efficacy, tolerability and safety, and patient's preference of budesonide foam vs. budesonide enema.Methods Patients with active ulcerative proctitis or proctosigmoiditis (clinical activity index >4 and endoscopic index ≥4) were eligible for this double‐blind, double‐dummy, randomized, multicentre study. They received 2 mg/25 mL budesonide foam and placebo enema (n = 265), or 2 mg/100 mL budesonide enema and placebo foam (n = 268) for 4 weeks. Primary endpoint was clinical remission (clinical activity index ≤4) at the final/withdrawal visit (per protocol).Results A total of 541 patients were randomized – 533 were evaluable for intention‐to‐treat analysis and 449 for per protocol analysis. Clinical remission rates (per protocol) were 60% for budesonide foam and 66% for budesonide enema (P = 0.02362 for non‐inferiority of foam vs. enema within a predefined non‐inferiority margin of 15%). Both formulations were safe and no drug‐related serious adverse events were observed. Because of better tolerability and easier application most patients preferred foam (84%).Conclusion Budesonide foam is as effective as budesonide enema in the treatment of active ulcerative proctitis or proctosigmoiditis. Both budesonide formulations are safe, and most patients prefer foam.